John Michael Soucie1,2, Connie H Miller1,2, Brandi Dupervil1, Binh Le1, Tyler W Buckner3. 1. Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2. Synergy America, Inc., Duluth, GA, USA. 3. Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA.
Abstract
INTRODUCTION: Estimates of the size and characteristics of the US haemophilia population are needed for healthcare planning and resource needs assessment. A network of comprehensive haemophilia treatment centres (HTCs) located throughout the United States receives federal support for diagnosis and management of haemophilia and other rare bleeding disorders. AIM: Estimate the incidence and prevalence of haemophilia among US males using the HTC network. METHODS: During the period 2012-2018, de-identified surveillance data were collected on all males who visited an HTC that included year of birth, gender, race, Hispanic ethnicity, residence zip code, haemophilia type and severity. Data from all patients were used to calculate period prevalence by haemophilia type, severity and state of residence. Data from a subset of patients born 1995-2014 were used to estimate incidence rates over the 20-year period. RESULTS: During the period, 21 748 males with haemophilia visited the HTCs resulting in an age-adjusted prevalence of 15.7 cases per 100 000 males (12 for haemophilia A and 3.7 for haemophilia B). Prevalence was higher among whites (15.1) than blacks (12.4) or Hispanics of either race (12.4). State-specific prevalence varied from 1.6 to 23.3 cases per 100 000. Based on 9587 males born during the index period, the average haemophilia incidence was 1 case per 4334 live male births. CONCLUSION: Based on these data, we estimate that there are between 29 761 and 32 985 males with haemophilia living in the United States today, the majority of whom receive comprehensive care in specialized clinical centres. Published 2020. This article is a U.S. Government work and is in the public domain in the USA.
INTRODUCTION: Estimates of the size and characteristics of the US haemophilia population are needed for healthcare planning and resource needs assessment. A network of comprehensive haemophilia treatment centres (HTCs) located throughout the United States receives federal support for diagnosis and management of haemophilia and other rare bleeding disorders. AIM: Estimate the incidence and prevalence of haemophilia among US males using the HTC network. METHODS: During the period 2012-2018, de-identified surveillance data were collected on all males who visited an HTC that included year of birth, gender, race, Hispanic ethnicity, residence zip code, haemophilia type and severity. Data from all patients were used to calculate period prevalence by haemophilia type, severity and state of residence. Data from a subset of patients born 1995-2014 were used to estimate incidence rates over the 20-year period. RESULTS: During the period, 21 748 males with haemophilia visited the HTCs resulting in an age-adjusted prevalence of 15.7 cases per 100 000 males (12 for haemophilia A and 3.7 for haemophilia B). Prevalence was higher among whites (15.1) than blacks (12.4) or Hispanics of either race (12.4). State-specific prevalence varied from 1.6 to 23.3 cases per 100 000. Based on 9587 males born during the index period, the average haemophilia incidence was 1 case per 4334 live male births. CONCLUSION: Based on these data, we estimate that there are between 29 761 and 32 985 males with haemophilia living in the United States today, the majority of whom receive comprehensive care in specialized clinical centres. Published 2020. This article is a U.S. Government work and is in the public domain in the USA.
Authors: R Kulkarni; J M Soucie; J Lusher; R Presley; A Shapiro; J Gill; M Manco-Johnson; M Koerper; P Mathew; T Abshire; D Dimichele; K Hoots; R Janco; D Nugent; S Geraghty; B Evatt Journal: Haemophilia Date: 2009-07-22 Impact factor: 4.287
Authors: Alfonso Iorio; Jeffrey S Stonebraker; Hervé Chambost; Michael Makris; Donna Coffin; Christine Herr; Federico Germini Journal: Ann Intern Med Date: 2019-09-10 Impact factor: 25.391
Authors: Robert F Sidonio; Fatima D Mili; Tengguo Li; Connie H Miller; William C Hooper; Michael R DeBaun; Michael Soucie Journal: Am J Hematol Date: 2014-05-21 Impact factor: 10.047
Authors: Amanda I Okolo; John Michael Soucie; Scott D Grosse; Christopher Roberson; Isaac A Janson; Martha Allen; Amy D Shapiro Journal: Haemophilia Date: 2019-03-29 Impact factor: 4.287
Authors: Helmut Schweiger; Judit Rejtő; Christoph J Hofbauer; Verena Berg; Peter Allacher; Karl Zwiauer; Clemens Feistritzer; Gerhard Schuster; Cihan Ay; Birgit M Reipert; Ingrid Pabinger Journal: Blood Adv Date: 2022-02-08
Authors: Jonathan R Day; Clifford Takemoto; Anjali Sharathkumar; Sarah Makhani; Ashwin Gupta; Stephanie Bitner; Cassandra D Josephson; Evan M Bloch; Aaron A R Tobian; Lakshmanan Krishnamurti; Ruchika Goel Journal: Haemophilia Date: 2022-04-12 Impact factor: 4.263
Authors: Michelle Witkop; Maria Santaella; Cynthia D Nichols; Angela Y Lambing; Kimberly Baumann; Randall G Curtis; Christi Humphrey; Thomas J Humphries; Jennifer Newman; Nancy Durben; Rhonda Fritz; Kimberly Mauer; Constance B Thibodeaux; Emily Wheat; Tyler Buckner Journal: Pain Med Date: 2022-02-01 Impact factor: 3.750